http://www.duratatherapeutics.com/ http://finance.yahoo.com/q/ks?s=DRTX+Key+Statistics Durata Therapeutics, Inc., a pharmaceutical company, focuses on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Its principal product is the dalbavancin, an intravenous antibiotic product candidate, which is in Phase III clinical trials for the treatment of patients with acute bacterial skin and skin structure infections. The company is headquartered in Morristown, New Jersey.
